Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst

Wedbush initiated coverage on Solid Biosciences, Inc. SLDB, a gene therapy company focused on treating Duchenne muscular dystrophy (DMD).DMD is a genetic disease that causes progressive muscle weakness and wasting.SGT-003 is the leading program in Solid Biosciences' pipeline, with plans to advance additional projects toward clinical trials in 2025.The therapy uses the AAV-SLB101 capsid and a specialized cargo (nNOS binding domain) to potentially boost dystrophin expression compared to earlier-generation tre ...